Collegium Pharmaceutical (COLL) Other Accumulated Expenses (2014 - 2025)

Collegium Pharmaceutical's Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $6.4 million for Q3 2025.

• On a quarterly basis, Other Accumulated Expenses fell 11.27% year-over-year to $6.4 million in Q3 2025; TTM through Sep 2025 was $6.4 million, a 11.27% decrease from a year earlier, with the FY2024 full-year figure at $13.1 million, up 264.44% from the prior year.
• Other Accumulated Expenses climbed to $6.4 million in Q3 2025 per COLL's latest filing, from $4.3 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $14.3 million in Q2 2021 and bottomed at $1.0 million in Q3 2021.
• The 5-year median for Other Accumulated Expenses is $7.0 million (2022), against an average of $7.0 million.
• Across the five-year window, Other Accumulated Expenses jumped 1341.29% in 2021 and plunged 78.44% in 2022, its largest moves.
• Year by year, Other Accumulated Expenses stood at $9.9 million in 2021, then sank by 65.28% to $3.4 million in 2022, then advanced by 4.41% to $3.6 million in 2023, then jumped by 264.44% to $13.1 million in 2024, then plunged by 51.41% to $6.4 million in 2025.
• Per Business Quant, the three latest COLL Other Accumulated Expenses figures stand at $6.4 million (Q3 2025), $4.3 million (Q2 2025), and $4.8 million (Q1 2025).